Triple

T17377777
Position Surface form Disambiguated ID Type / Status
Subject Bicycle Therapeutics E422484 entity
Predicate targets P860 FINISHED
Object Nectin-4 (via BT8009) — NE NERFINISHED

How this triple was built (3 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Nectin-4 (via BT8009) | Statement: [Bicycle Therapeutics, targets, Nectin-4 (via BT8009)]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: Nectin-4 (via BT8009)
Context triple: [Bicycle Therapeutics, targets, Nectin-4 (via BT8009)]
  • A. TAK-079
    TAK-079 is an investigational human monoclonal antibody designed to deplete CD38-expressing cells, primarily being developed for the treatment of multiple myeloma and certain autoimmune diseases.
  • B. CNK4
    CNK4 is the ICAO airport code assigned to Parry Sound Area Municipal Airport in Ontario, Canada.
  • C. LOXO-195
    LOXO-195 is a next-generation, highly selective TRK inhibitor developed to treat cancers that have developed resistance to earlier TRK-targeted therapies.
  • D. LOXO-292
    LOXO-292, also known as selpercatinib, is a targeted cancer therapy that selectively inhibits RET kinase and is used to treat certain RET-altered thyroid and lung cancers.
  • E. LOXO-305
    LOXO-305 is a highly selective, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor being developed as a targeted therapy for B-cell malignancies such as chronic lymphocytic leukemia.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07 
Target entity: Nectin-4 (via BT8009)
Target entity description: Nectin-4 (via BT8009) is a cell-adhesion protein overexpressed on certain cancer cells and exploited as a tumor-associated antigen for targeted cancer therapy.
  • A. TAK-079
    TAK-079 is an investigational human monoclonal antibody designed to deplete CD38-expressing cells, primarily being developed for the treatment of multiple myeloma and certain autoimmune diseases.
  • B. CNK4
    CNK4 is the ICAO airport code assigned to Parry Sound Area Municipal Airport in Ontario, Canada.
  • C. LOXO-195
    LOXO-195 is a next-generation, highly selective TRK inhibitor developed to treat cancers that have developed resistance to earlier TRK-targeted therapies.
  • D. LOXO-292
    LOXO-292, also known as selpercatinib, is a targeted cancer therapy that selectively inhibits RET kinase and is used to treat certain RET-altered thyroid and lung cancers.
  • E. LOXO-305
    LOXO-305 is a highly selective, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor being developed as a targeted therapy for B-cell malignancies such as chronic lymphocytic leukemia.
  • F. None of above. chosen

Provenance (2 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69d889d6535c81908be333c01deaec4e completed April 10, 2026, 5:25 a.m.
NER Named-entity recognition batch_69e43a6ea56c8190b56d966ccf2c91f7 completed April 19, 2026, 2:14 a.m.
Created at: April 10, 2026, 5:45 a.m.